Bacterial meningitis (BM) affects the central nervous system (CNS) and is a significant long-term sequela for 50% of survivors globally. Resource-poor areas have a higher prevalence of acute bacterial meningitis than resource-rich ones. The pathogenesis of BM involves intricate pathways linked to bacterial survival and proliferation in the circulation, increased blood-brain barrier (BBB) permeability, oxidative stress, and an overactive inflammatory response in the central nervous system (CNS). Drug-resistant bacteria make treating meningitis more challenging, as the morbidity rate for BM is still very high. There has been promising progress in neurology recently for drug supplements that effectively prevent and treat BM. There have been hopeful advancements in neurology recently for medication supplements that effectively prevent and cure BM. Numerous in vivo and in vitro researches have gone into detail on how drugs affect BM and its important mechanism. However, prevention of BM at community and individual levels is vital and can be achieved via various strategies. Some of the strategies are particular hygiene protocols, isolation, social distancing, quite smoking, immunoglobulin treatments and many other methods. Yet, vaccinations still remain the best stratagem against the risk of bacterial meningitis and several other severe infections at the level of the community.












